Clinical Trial Search

Primary: mITT Primary Effectiveness Endpoint. Based on Subjects With 100% Occlusion of the Aneurysm Without Clinically Significant Stenosis of the Parent Artery, and Without Any…

Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445

Primary: Change in Oxygen Delivery in Vulnerable Brain Regions — 3.7; 4.3 ml/100g/min — p=0.001

Primary: Prognostic Value of the MAFA (Mean Aneurysm Flow Amplitude) Ratio With Respect to Full Aneurysm Occlusion Within 12 Months — 0.540 probability

Primary: The Percentage of Participants With the Occurrence of Major Stroke in the Territory Supplied by the Treated Artery or Neurological Death at 12-Months Post Procedure…

Primary: Number of Participants With Neurologic Death or Major Ipsilateral Stroke Within 12 Month Follow-up Period. — 5 Participants

Primary: Change From Baseline to Day 2 in Cerebrovascular Reactivity as Measured by the Slope (Amplitude Over Time to Peak) From Visual Task-evoked Functional Magnetic Resonance…

Primary: Primary Safety Endpoint: Percentage of Participants With Death of Any Non-accidental Cause or Major Disabling Stroke Within First 30 Days After Treatment or Major…

Primary: Number of Participants Who Achieved a Raymond Score I/II or Experienced Neurological Death — 0; 29 Participants

Primary: Number of Participants With the Occurrence of Major Ipsilateral Stroke or Neurologic Death and Occurrence of Ipsilateral Stroke or Neurologic Death. — 6; 10 Participants…

Primary: Number of Patients With Deep Vein Thrombosis for Safety Assessment. — 0; 3; 0; 0 participants

Primary: Change in the Growth Rate of Abdominal Aortic Aneurysm — 1.77; 1.81; 1.66 mm — p=0.78

Primary: Number of Patients With Aneurysm Recurrence Post Surgery — 11; 41 participants — p=0.002

Primary: Occurrence of Clinical Deterioration Due to Delayed Cerebral Ischemia (DCI) From Study Drug Initiation up to 14 Days Post-study Drug Initiation — 32; 35 Participants…

Primary: Depression — 12.33; 6 units on a scale

Primary: Fraction of Time That Brain Oxygen Levels Are Below the Critical Threshold of 20 mm Hg . — 0.15; 0.44 Proportion

Primary: Percentage of Participants With Freedom From Clinical or Radiographic Central Nervous System (CNS) Infarction — 74.4; 68.0; 67.6 percentage of participants — p=0.22

Primary: Progression-free Survival (PFS) — 91.3 percentage of participants

Primary: Packing Density With the Number of Coils Implanted — 37.9 percentage of aneurysm volume

Primary: Hemostasis at the Target Bleeding Site (TBS) at 6 Minutes Following Treatment Application. Hemostasis is Defined as no Detectable Bleeding at the TBS. — 99.2; 100 % of…

Primary: Absence of the Following Procedural Safety Events: Death, Stroke, Myocardial Infarction, Bowel Ischemia, Paraplegia, Respiratory Failure, Renal Failure, Procedural Blood…

Primary: Mean Plasma Nitrite Concentration (Micromol/L) — 4.2; 4.3; 2.6 micromol/L

Primary: Blood Flow and Perfusion — 26.8 ml/min/100g — p=0.004

Primary: Mean Blood Flow Velocity in Middle Cerebral Artery — 63.7; 61.8 cm/s — p=0.554

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: Number of Participants With Raymond Class I Complete Obliteration at 12 Months — 98 Participants

Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF

Primary: Incidence of Seizure — 2; 1; 0; 0 Participants

Primary: Hyponatremia — 7; 10 participants

Primary: Number of Patients Experiencing of Dose-limiting Toxicity (Cohort 1) — 0 participants